News & Events about Arcus Biosciences Inc.
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Companys Board of Directors granted four new employees options to purchase a total of 11,250 shares of the...
MarketWatch.com - GOOG
1month ago
New data on a cancer drug trial from Gilead Sciences and Arcus Biosciences are resurfacing debate around the class of cancer drugs known as anti-TIGITs...
Shares of Arcus Biosciences, Inc. (NYSE:RCUS Get Rating) have been given an average rating of Moderate Buy by the nine brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy ...
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies Optimism Building for Advancing Pancreatic Cancer Treatment Therapies PR Newswire PALM BEACH, Fla., Dec. 1, 2022 PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Pancreatic cancer accounts...
Business Wire
2 months ago
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score...